Everything below concerns amino acid substitution. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-11-01. Numbers and descriptions here follow the published literature rather than marketing material.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Synthetic cyclic heptapeptide |
| Molecular mass | Approximately 1024 g/mol | Depends on counter-ion content |
| Appearance | White to off-white powder | Commonly supplied as a lyophilised solid |
| Solubility | Freely soluble in water | Also dissolves in common aqueous buffers |
| Typical storage | -20 degrees Celsius, desiccated | Protect from light and repeated freeze-thaw |
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
=== Ectopic fat === Ectopic fat is the storage of triglycerides in tissues other than adipose tissue, that are supposed to contain only small amounts of fat, such as the liver, skeletal muscle, heart, and pancreas. This can interfere with cellular functions and hence organ function and is associated with insulin resistance in type 2 diabetes. It is stored in relatively high amounts around the organs of the abdominal cavity, but is not to be confused with visceral fat. The specific cause for the accumulation of ectopic fat is unknown. The cause is likely a combination of genetic, environmental, and behavioral factors that are involved in excess energy intake and decreased physical activity. Substantial weight loss can reduce ectopic fat stores in all organs and this is associated with an improvement of the function of those organs. In the latter case, non-invasive weight loss interventions like diet or exercise can decrease ectopic fat (particularly in heart and liver) in overweight or obese children and adults.
== Clinical Significance == In diseases related to the cartilage, the territorial matrix undergoes structural and material changes, leading to degradation of the joints, like in the case of osteoarthritis. Osteoarthritis occurs when the proteoglycans and collagen fibers degrade and become disorganized. Consequently, the decreased mechanical support makes chondrocytes more vulnerable to damage. Matrix-degrading enzymes including matrix metalloproteinases (MMPs) target the region which can accelerate cartilage degradation. Attempts to restore a functional territorial matrix is a particular area of interest in tissue engineering and cartilage repair, since its structure significantly contributes to optimal mechanical and biochemical behavior. Studies on biomimetic proteoglycans, which mimic the natural existing component of the ECM, and their effect on neighboring cartilage regions have shown promising results for strengthening cartilage with osteoarthritis. Additionally, biomaterials designed to mimic native composition and mechanical properties of cartilage, especially those with synthetic proteoglycans or collagen, have shown experimental promise. In combination with these structures, the durability of engineering cartilage may be enhanced by regenerating the territorial matrix and could improve integration with native tissue.
== External links == Newspaper clippings about Prince August Wilhelm of Prussia in the 20th Century Press Archives of the ZBW Information about Prince August Wilhelm of Prussia in the Reichstag database
==== Animal substances ==== Some animal parts used include cow gallstones, hornet nests, leeches, and scorpion. Other examples of animal parts include horn of the antelope or buffalo, deer antlers, testicles and penis bone of the dog, and snake bile. Some TCM textbooks still recommend preparations containing animal tissues, but there has been little research to justify the claimed clinical efficacy of many TCM animal products. 968+8956
The downregulation of ALAS1 lowers the levels of neurotoxic intermediates that cause AHP symptoms. Years of research have led to a greater understanding of siRNA therapies beyond those affecting the liver. As of 2019, Alnylam Pharmaceuticals was involved in therapies that may treat amyloidosis and CNS disorders like Huntington's disease and Alzheimer's disease. They have also partnered with Regeneron Pharmaceuticals to develop therapies for CNS, eye, and liver diseases. As of 2020, Onpattro and Givlaari were available for commercial application, and two siRNAs, lumasiran (ALN-GO1) and inclisiran, have been submitted for new drug application to the FDA. Several siRNAs are undergoing phase 3 clinical studies, and more candidates are in the early developmental stage. In 2020, Alnylam and Vir Pharmaceuticals announced a partnership and have started working on an RNAi therapy that would treat severe cases of COVID-19. Other companies that have had success in developing a pipeline of siRNA therapies include Dicerna Pharmaceuticals, partnered with Eli Lilly and Company, and Arrowhead Pharmaceuticals, partnered with Johnson and Johnson. Several other large pharmaceutical companies, such as Amgen and AstraZeneca, have also invested heavily in siRNA therapies, seeing potential success in this area of biological drugs.
Sources: en.wikipedia.org
== References == CDBaby.com BBC Radio 2 Interview (The Weekender with Matthew Wright - 3rd Nov 2006) The Times Newspaper (UK): Knowledge Section (Saturday 26 Nov 2006) Future Music Magazine interview (Nov 2005)
Sandbuster Sand-Resistant Oil SPF 2 Tropical Deluxe SPF 4 Mega-Tan SPF 4 Mademoiselle (SPF 4, SPF 8, and SPF 15) All Day (SPF 4, SPF 8, SPF 15, SPF 30, Kids SPF 30, and Gentle Block SPF 30) SPF + Color (SPF 8, SPF 15, SPF 20) - line renamed to "Sunless Tanning Creme with Sunblock" Sunless (Light, Dark, Deep Dark, Tanning Spray Dark, and Tanning Spray Deep Dark) Apres Soleil After Sun Revitalizing Aloe Mist Apres Soleil After Sun Moisture Replenishing Lotion Orange Gelee (SPF 4, SPF 8, SPF 15, and SPF 30) Ecran Solaire (SPF 15 and SPF 30 Kids) - Canada Product development scientists at Pfizer CHCG were John A. Scott (group manager), Alice Scheiner (after sun and high-SPF products), Eric M. Stroud (sunless products), Judy Meyer, Andrew Ortega, and Mary Williams (packaging). Two innovations in 1,3-dihydroxyacetone stability were invented during this time. The entire brand was eventually divested on October 7, 1999, to Schering-Plough.
List of projectile attacks from Lebanon on Israel and the Golan Heights Outline of the Gaza war Palestinian insurgency in South Lebanon Hamas in Lebanon April 2023 Palestinian rocket attacks on Israel Lebanese displacement during the Israel–Hezbollah conflict (2023–present) Ali Damoush
Wheeler was awarded the Lab on a Chip Pioneers in Miniaturization Award (2017), an E.W.R. Steacie Fellowship from the Natural Sciences and Engineering Research Council of Canada (NSERC) (2015), a Connaught Foundation McLean Fellowship (2014), the Joseph Black Award from the Royal Society of Chemistry (2012), the Arthur F. Findeis Award from the American Chemical Society (2012), the Young Innovator Award in Analytical Chemistry (2011), and a Sloan Research Fellowship (2009). In January 2024, Wheeler was honored with the Ricardo Aroca Award, recognizing his contributions to analytical chemistry and advancing lab-on-a-chip techniques, particularly through the use of digital microfluidics (DMF), which enables precise manipulation of liquid droplets on electrode arrays. The Award is bestowed upon a scientist living in Canada who has made a notable contribution to the discipline of analytical chemistry while conducting research within the country.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide and an analogue of alpha-melanocyte-stimulating hormone. The molecule is produced by chemical synthesis rather than extracted from a biological source.
It is shorter than the native hormone and carries a cyclic constraint that improves stability. These changes raise receptor potency and slow breakdown relative to the naturally occurring peptide.
Published accounts date its development to the 1980s, when researchers were generating analogues of melanocyte-stimulating hormone. That work aimed to produce more stable compounds for studying pigmentation biology.
It is a synthetic cyclic heptapeptide and a non-selective melanocortin receptor agonist. Structurally it is modelled on alpha-melanocyte-stimulating hormone, a peptide that occurs naturally in the body.